Phreesia (PHR) to Release Quarterly Earnings on Monday

Phreesia (NYSE:PHR) is scheduled to release its earnings data after the market closes on Monday, December 9th. Analysts expect Phreesia to post earnings of ($0.29) per share for the quarter. Phreesia has set its FY 2025 guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.06. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. The business had revenue of $102.12 million during the quarter, compared to the consensus estimate of $101.76 million. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Phreesia Stock Up 3.6 %

PHR opened at $21.03 on Monday. The stock’s 50 day moving average price is $20.43 and its 200 day moving average price is $21.84. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.77 and a quick ratio of 1.77. The stock has a market cap of $1.21 billion, a P/E ratio of -11.68 and a beta of 0.94. Phreesia has a 12 month low of $14.55 and a 12 month high of $29.16.

Analyst Upgrades and Downgrades

PHR has been the topic of a number of recent analyst reports. Royal Bank of Canada restated a “sector perform” rating and set a $23.00 price objective on shares of Phreesia in a research note on Friday, September 27th. JMP Securities restated a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Thursday, September 5th. Robert W. Baird increased their price objective on shares of Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Friday, September 6th. Canaccord Genuity Group reissued a “buy” rating and set a $34.00 target price on shares of Phreesia in a report on Thursday, September 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Phreesia in a research note on Thursday, September 5th. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $29.42.

Insider Transactions at Phreesia

In related news, insider Yvonne Hui sold 2,791 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.92, for a total transaction of $58,387.72. Following the transaction, the insider now directly owns 27,228 shares of the company’s stock, valued at approximately $569,609.76. The trade was a 9.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Balaji Gandhi sold 3,502 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total value of $81,421.50. Following the completion of the sale, the chief financial officer now directly owns 98,578 shares of the company’s stock, valued at approximately $2,291,938.50. This represents a 3.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,997 shares of company stock valued at $667,943 over the last three months. Company insiders own 5.80% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.